Literature DB >> 27663955

Renoprotection in LEADER and EMPA-REG OUTCOME.

Marcel H A Muskiet1, Lennart Tonneijck2, Erik J M van Bommel2, Mark M Smits2, Daniël H van Raalte2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27663955     DOI： 10.1016/S2213-8587(16)30214-5

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  3 in total

Review 1.  Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review.

Authors:  Davida Kruger; Virginia Valentine
Journal:  Diabetes Ther       Date:  2020-05-13       Impact factor: 2.945

2.  Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program.

Authors:  Carlos Morillas; Javier Escalada; Rafael Palomares; Diego Bellido; Fernando Gómez-Peralta; Antonio Pérez
Journal:  Diabetes Ther       Date:  2019-07-29       Impact factor: 2.945

3.  Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.

Authors:  Nienke M A Idzerda; Lindsay E Clegg; Adrian F Hernandez; George Bakris; Robert C Penland; David W Boulton; M Angelyn Bethel; Rury R Holman; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2020-02-03       Impact factor: 6.577
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.